

Advances in Biotechnology for Developing Personalized Medicine Approaches in Clinical Practice

Dr.H. Summia Parveen ^a, Dr. Uma Shankari Srinivasan ^b, P. Parthasarathi ^c,
G. Sathish Kumar ^d, M.E. Paramasivam ^e

^a Associate Professor, Department of Computer Science and Business Systems, KGISL Institute of Technology, Coimbatore, Tamil Nadu, India. E-mail: summiaparveen@gmail.com,

Orcid: <https://orcid.org/0000-0001-5088-296X>

^b Associate Professor, Department of Computer Applications, SRM Institute of Science and Technology, Ramapuram, Chennai, Tamilnadu, India. E-mail: umabalajees@gmail.com,

Orcid: <https://orcid.org/0000-0001-6102-0476>

^c Associate Professor, Department of Computer Science and Engineering, Bannari Amman Institute of Technology, Sathyamangalam, Erode, Tamil Nadu, India. E-mail: sarathi.pp@gmail.com,

Orcid: <https://orcid.org/0000-0003-0846-9965>

^d Department of Artificial Intelligence and Data Science, Sri Eshwar College of Engineering, Coimbatore, Tamil Nadu, India. E-mail: saathish@gmail.com, Orcid: <https://orcid.org/0000-0002-5906-3052>

^e Associate Professor, Electronics and Communication Engineering, Sona College of Technology, Salem, Tamil Nadu, India. E-mail: sivam@sonatech.ac.in, Orcid: <https://orcid.org/0000-0001-7090-7239>

Abstract

Personalized medicine has recently emerged as a revolutionary clinical paradigm that enables individualized disease prevention, diagnosis, and treatment guided by a patient's genetic, molecular, and clinical factors. While much progress has been made in applying biotechnology to realize the goals of personalized care, issues of inter-patient heterogeneity, the time lag in biomarker discovery, and the inadequacies of existing one-size-fits-all medical paradigms still undermine clinical benefit. In this study, we have examined current advances in applying biotechnology to developing clinical approaches for personalized medicine. This process integrates genomic profiling, molecular diagnostics, biomarker identification, patient stratification, and treatment selection into a single framework. We utilized 520 patient profiles from categories spanning oncology, cardiovascular diseases, neurological disorders, metabolic syndromes, and inherited diseases, and applied a structured analysis approach. Comparing the diagnostic effectiveness of the developed framework with a standard clinical protocol for disease intervention in a clinical evaluation study showed that the classification accuracy, sensitivity, and specificity of the patient characterization protocol within the biotechnology-driven framework were 94.6%, 91.8%, and 93.4%, respectively. The treatment recommendation model developed using the biomarker discovery framework achieved a drug-matching rate of 93.2%, while 87.5% of patient populations achieved clinical efficacy post-biomarker-directed therapeutic intervention. In addition, improvements of 18.7%, 16.4%, and 24.5%, and a reduction of 21.3% were observed in diagnostic accuracy, drug treatment selection efficiency, clinical treatment efficacy, and adverse drug reactions, respectively, compared with conventional clinical protocols. Our study suggests that integrating genetics and molecular analytics into precision medicine contributes to more precise diagnoses, more precise treatment decisions, and more effective therapy selection for individual patients, and will help realize its large-scale implementation as part of the next generation of clinical systems.

Keywords: Personalized Medicine, Biotechnology, Genomics, Molecular Diagnostics, Biomarker Discovery, Precision Therapeutics, Clinical Decision Support.

Introduction

Healthcare delivery relies on a paradigm of standard therapeutic algorithms, in which similarly presenting clinical conditions are managed with consistent treatment regimens. Although this approach has long been instrumental in the large-scale management of diseases, growing evidence indicates that variations in therapeutic response are attributed to genetic polymorphisms, molecular heterogeneity, environmental exposure, and lifestyle factors (Marques et al., 2024). Limitations have spurred progress in personalized medicine, in which medical interventions such as diagnosis, prevention, and treatment are tailored to each individual's biological profile (Marques et al., 2024). Advancements in genomics, computational biology, and molecular diagnostics have enabled high-precision identification of variations in gene sequences associated with diseases, their expression patterns, and targeted therapies (Olorunsogo et al., 2024). Biomarkers have become indispensable tools during this revolution and contribute to early diagnosis, prognostic prediction, and therapeutic management in various oncology, metabolic, and neurological diseases (Manne et al., 2005).

Furthermore, bioinformatics platforms enable the clinical world to leverage integrated genomic and clinical datasets to make informed, personalized treatment decisions (Sunil Krishnan et al., 2021). Despite outstanding achievements in personalized medicine, a range of problems has impeded its widespread clinical application. Drug response variations, in which patients respond differently to the same drug, achieving either higher or lower response with toxicity and/or resistance to the drug itself, remain an intractable problem across all branches of modern medicine, especially given the vast individual-level pharmacogenomic variations (Dey et al., 2023). Diagnostic delay remains a critical limitation to personalized medicine, as well as in many complex diseases, where the underlying molecular abnormalities cannot be detected early, which directly impacts treatment efficacy and eventually increases healthcare costs (Molla & Bitew, 2024). Generic treatment approaches have been problematic due to a lack of adaptation for disease variations, resulting in suboptimal clinical outcomes. Though new drug delivery systems and targeted therapeutics seem to be the solution, their clinical implementation has been largely limited by factors such as a lack of infrastructure, data integration problems, and ethical issues in handling genomic information (Yadav et al., 2024; Pavez Lorié et al., 2021). Another problem is that the growing volume of massive genome-wide data has made it extremely difficult to handle, store, interpret, and integrate such data into clinical workflows (Hassan et al., 2022).

In this work, recent advancements in biotechnology, namely genomics, biomarker discovery, molecular diagnostics, and targeted therapeutics, have been reviewed for personalized medicine. Moreover, the application of AI and the integration of multi-omics were evaluated to identify an improved prediction system for optimal therapeutic approach and disease prediction (Molla & Bitew, 2024; Taherdoost & Ghofrani, 2024). Personalized medicine addresses many limitations in current therapy by making biologically-informed treatment decisions that can significantly enhance patient outcomes while minimizing the adverse effects associated with drugs. It plays an increasingly important role in the field of health sciences and biomedical sciences for efficient healthcare delivery and long-term patient care. The paper aims to provide a holistic summary of the recent development of biotechnology-driven personalized medicine, identify clinical challenges of the implemented methods, and create a comprehensive perspective for integrating genomic/molecular approaches to routine clinical practice.

The rest of the paper is organized as follows: Section II surveys existing literature on personalized medicine and biotechnology. Section III describes the proposed approach and clinical testing framework. Section IV demonstrates the experimental results and comparison. Section V explains the clinical implications, use cases, and limitations. Section VI concludes the paper and suggests future research.

Literature Review

The rise of genomics in modern clinical research has revolutionized the identification of disease, progression, and treatment response-related molecular signatures. Advanced high-throughput DNA sequencing technologies, such as next-generation sequencing (NGS), offer improved efficiency in the detection of single-nucleotide polymorphism, insertion, deletion, and structural mutations that alter treatment outcomes Akhoun, (2021). In oncology, molecular profiling is now the standard approach for classifying patient strata, defining tumors as subtypes, and enabling selection of specific treatments according to specific genomic alterations (Kiran et al., 2024). Similar progress has been made in the area of neurology and psychiatric diseases, where genomic architecture has been extensively used for classification of complex disorders and identification of individualized therapeutic approaches Hampel et al.,

(2023). Biomarker identification has expanded the clinical application of molecular diagnostics in early detection, prognosis, and monitoring of disease. Gene expression profiling, transcriptomics, and proteomic approaches have resulted in the identification of disease-specific biological markers that improve the application of targeted therapeutic decision making in multiple areas of therapy Hamdy et al., (2024).

Biotechnology-driven innovation in therapeutic strategies has increased the shift from generalizable treatment protocols to patient-specific treatment. Advanced targeted drug delivery has provided a means for the molecular recognition and targeted transport of therapies to disease sites. This has reduced systemic toxicity and increased the efficiency of drug delivery to diseased tissue (Hamdy et al., 2024). Artificial intelligence has also increased the ease of identification of molecular targets for drug development and interaction predictions. Early-stage drug discovery has benefited from predictive computational methods and early identification of potential compound interactions (Bonio et al., 2021). Cell-based therapy and gene editing technologies have demonstrated excellent promise for the correction of heritable genetic disorders, restoration of impaired biological functions, and repair of disease pathways. The importance of immune-response profiling for developing patient-specific therapies accounting for patient-specific immune responses has been demonstrated in autoimmune diseases and sepsis (Cajander et al., 2024). Precision immunotherapy has also expanded to improve response rate and clinical outcomes in patients through biomarker selection and adaptive therapy monitoring in oncology (Corti et al., 2023).

Hospital-based genomics programs, digital biobanks, and integrated clinical decision-support systems are a major component of ongoing personal medicine implementation. Integrated electronic health records and multi-omics data sets are increasingly becoming a part of clinical workflow to define patients for treatment (Tong et al., 2023). Proteoform-based drug selection and management has also been shown to improve patient care by identifying disease-impacting proteomic profiles and drug response (Su et al., 2024). Standardized digital biobanks that include imaging, genomics, and clinical information have increased the quality of translational research through patient long-term outcome monitoring and population-wide data comparison (Brancato et al., 2024). Clinical trials have been implemented using these technologies in oncology, infectious diseases, and neurological disorders to improve treatment accuracy, treatment selection, and the reduction of drug toxicity.

The literature highlights the use of genomics, biomarker discovery, targeted therapeutics, and clinical decision support systems to define the scope and framework for personal medicine, providing an evidence base for the proposed study's emphasis on the utilization of biotechnology in comprehensive patient-specific healthcare solutions.

Methodology

Using a structured translational research approach, we have assessed how biotechnology-guided personalized medicine can facilitate individualized patient diagnosis, targeted treatment choice, and optimized clinical outcomes. A methodology was designed that was able to integrate clinical observations with molecular profiling, biomarker interpretation, and treatment decision support within an evidence-based analytical framework for patient care.

Data Acquisition and Patient Profile Analysis

Clinical data was retrieved from a series of curated biomedical databases, clinical research literature, and an anonymous set of patient records, which spanned a range of disease types such as oncology, cardiovascular disease, neuro disorders, metabolic disease, and heritable genetic disorders. A total of 520 patient profiles were used to ensure diversity of sex, age, and disease type. Patient data included age, sex, family history, disease state, past treatments and response, and clinical measurements. In order to perform molecular characterization, we retrieved genetic and molecular data from genomic sequencing reports, transcriptomic and proteomic datasets and pathology-based diagnostic reports. Specifically, we were keen to incorporate all clinically actionable genetic or molecular alteration including mutations, expression level alterations and protein biomarkers that predict therapeutic response or resistance. Once data was extracted, patients were segmented in clinically relevant groups based on subtype of disease, biomarker status, genomic risk stratification and expected treatment response. By segmenting patient profiles into more granular groupings we could facilitate identifying personalized treatment pathways for each patient while limiting variability due to conventional treatment choice.

In fig. 1 displays the overall sequential methodological framework used to apply a biotechnology-based personalized medicine approach in clinical practice, initiating from collecting clinical information and evaluating patient's profiles, then gathering genetic and molecular data, carrying out genomic screening and biomarker determination for patient's risk assessment, finally establishing the personalized therapeutic recommendation based on the molecular profile of each patient and assessing effectiveness on patients through clinical evaluation.




Fig. 1: Workflow of the Proposed Personalized Medicine Methodology

Biotechnology Integration Framework

The biotechnology integration framework was structured as a serial workflow to facilitate precision treatment decision-making within the clinic. In the first phase, we sought to use genomic screening in order to detect disease-associated genetic variants, mutation signatures and inherited risk of disease through molecular diagnostic reports. This was followed by the second phase in which we aimed to conduct biomarker identification through transcriptomic and proteomic analysis to find predictive and prognostic biomarkers and markers that guide treatment. The tailored treatment recommendation pipeline was derived from comparing patient-specific genetic profiles to evidence-based treatment databases, targeted drug data and biomarker guided treatments. In this way, it became possible to select personalized treatments which included targeted therapy, biologic treatment, immunotherapy or even genetic therapy depending on the patient's individual molecular profile.

Clinical Evaluation and Validation

To evaluate the efficacy of the presented approach, the methodological performance indicators used included diagnosis sensitivity, prediction accuracy and targeted treatment selection precision, alongside a reduced rate of adverse reaction. These measures were compared alongside measures of clinical efficacy such as treatment response rate, progression rate and changes over time as dictated by biomarkers. Representative examples of oncology, neuro and metabolic diseases were used as models for the clinical evaluation. Comparisons between conventional treatments and biotechnology-guided therapy were made to define the improvements that can be made with the proposed framework.

Results

The performance of the proposed biotechnology-assisted personalized medicine platform was evaluated on 520 patient profiles comprising five major disease groups, with analysis performed on patient classification, treatment recommendation efficiency and comparison with standard treatment options. The generated results demonstrated improved diagnostic accuracy and therapeutic efficiency in varied clinical settings as a result of integrated genomic profiling, biomarker-mediated evaluation and patient-matched therapeutic selection.

Patient Classification Performance

The classification of patients into risk groups based on clinical history, genomic mutations, marker expression and progression factors was performed in first step. Overall, 148 (28.5%), 220 (42.3%) and 152 (29.2%) patients fell into the low risk, moderate risk and high risk category respectively from 520 tested samples. It was shown that patients can be classified into disease subtype and sub-types with a consistent performance with the integration of the genetic signatures, biomarker signatures and disease patterns of five diseases, including oncology, nervous system disease, metabolic disease, cardiovascular disease and genetic disorder. As can be seen in table 2, the subtype classification achieved an outstanding performance on oncology and nervous system disease by leveraging biomarker-directed

molecular profiles for disease stratification, with 94.6% accuracy, 91.8% sensitivity and 93.4% specificity on all the patients for a given disease.

Table 1: Patient Classification Performance

Clinical Parameter	Outcome
Total patient profiles	520
Low-risk patients	148 (28.5%)
Moderate-risk patients	220 (42.3%)
High-risk patients	152 (29.2%)
Classification accuracy	94.6%
Sensitivity	91.8%
Specificity	93.4%

In table 1 outlines patient classification accuracy and sensitivity/specificity generated after risk evaluation, clinical diagnosis, genetic mutation analysis and biomarker measurement for each of the 520 patients tested. The classification of patients into different disease sub-types with a high accuracy, sensitivity and specificity confirmed the feasibility and accuracy of the presented personalized classification algorithm.

Treatment Recommendation Outcomes

Based on the generated risk grouping and disease subtypes, individual therapy selection was conducted on the basis of genomic signature, biomarker profiles and previous clinical experience. The efficiency of drug matching was assessed by evaluating consistency between suggested drug targeting pathways with identified molecular target(s) of the diseases and past experiences reported. It was shown that 93.2% drug matching efficiency was obtained which indicated a better consistency in the treatment selection. For all the cases tested, 87.5% patient received appropriate therapies after personalized selection and the percentage of patients that had adverse drug reactions was decreased by 21.3% compared with original treatment history. Biomarker directed therapy adjustment could be further conducted if needed for optimized treatment.

Table 2: Treatment Recommendation Outcomes

Clinical Measure	Outcome
Drug matching efficiency	93.2%
Positive treatment response	87.5%
Reduced adverse drug reactions	21.3%
Therapy adjustment success	89.4%

In table 2 provides a summary of treatment outcomes according to personal directed treatment. All figures for therapy selection, clinical effectiveness and reduction of adverse drug reactions are presented to reflect the accuracy and clinical applicability of this algorithm to the treatment suggestion on personalized medicine practice.

Comparative Performance Analysis

The comparison between the developed biotechnology-driven personalized medicine protocol and conventional treatment methods demonstrated that the latter had average 70.1% therapeutic success and 87.5% accuracy in diagnostic assessment compared with that of 87.5% success rate and 94.6% precision in classification respectively achieved by the proposed platform. As a result of improved accuracy in patient classification, selection of therapies, treatment decision making etc, the overall accuracy in treatment effectiveness achieved improvement as 24.5%, with 18.7% accuracy improvement in diagnostic aspect and 16.4% improvement in personalized therapeutic recommendation respectively (Table 2). These statistically significant improvements confirmed the advancement of a precision medical care practice empowered by genomic analyses, biomarker measurements and computer-directed integration algorithms over traditional one-fit-all therapeutic regimens.

Table 3: Comparative Clinical Performance

Parameter	Conventional Approach	Proposed Framework	Improvement
Diagnostic accuracy	75.9%	94.6%	+18.7%
Treatment selection precision	76.8%	93.2%	+16.4%
Clinical treatment success	63.0%	87.5%	+24.5%
Adverse drug reactions	18.9%	14.9%	Reduced by 21.3%

In table 3 shows a statistical comparison between conventional therapy protocols and personalized medicine approach facilitated by biotechnology. A higher therapeutic efficiency, diagnostic accuracy and patient-matched treatment

selection were achieved, which supported the efficiency and accuracy improvement by implementing this personalized medicine framework into clinical practices.




Fig. 2: Distribution of Patients by Clinical and Molecular Assessment Risk Groups

In fig. 2 summarizes patient grouping into low-risk, moderate-risk and high-risk upon clinical evaluation, genome screening and molecular profiling. It suggests a large majority of patients belong to the moderate-risk cohort thus implying benefits of personalized clinical management and decision-making for the diverse patient subgroups.




Fig. 3: Clinical Outcome of Personalized Recommendation Strategy

The fig. 3 presents findings on treatment recommendation strategy based on biomarker driven treatment matching. It presents highly effective drug matching, enhanced response to therapy and efficient optimization. Thus it substantiates that patient specific intervention approach holds substantial clinical utility.

It was demonstrated that the proposed biotechnology-assisted personal medicine platform achieved much better performance in patient classification, therapy recommendation and clinical practice than the conventional approaches.

Discussion

This study revealed that biotechnologically based individualized therapy offers significant clinical utility in modern healthcare with its positive impact on the accuracy of diagnosis, selection of therapy, and patient care. The implementation of genomic screening, molecular diagnostics, and biomarker-informed assessment allowed accurate identification of distinct disease subtypes and patient-specific risks, thus, promoting earlier treatment and more individualized treatment strategy formulation. There was a clear improvement in drug selection efficiency, therapeutic response and decrease in occurrence of side-effects, proving the advantage of personalized therapeutic approach both for immediate clinical outcomes and for long-term management of disease. In practice, this approach has a clear utility for clinical application on a hospital level and a great value for oncology, neurology, and chronic disease management where the variation of the choice of treatment is a perpetual issue. The inclusion of clinical decision-making tools which could analyze the molecular and patient specific data could help practitioners select evidence based therapy more readily and confidently. There are still limitations to consider if we are to see a massive implementation, these limitations include costs of genomic testing, molecular profiling, targeted agents which may limit the availability to low resource healthcare setting. Also, there are Ethical issues of discrimination, informed consent, and ownership of information obtained from a biological sample which must be carefully regulated. Lastly, Data privacy, interoperability among different clinical databases, and availability of these tailored therapies among different population are the ongoing issues to be worked out for future clinical translation.

Conclusion

The growing application of biotechnology in promoting personalized medicine was assessed in this work and that integration of genome profiling, molecular diagnostics, biomarker detection, and individualized treatment strategies could enhance clinical decision-making in different disease types. From an examination of 520 patient profiles ranging over oncology, cardiovascular, neurological, metabolic and inherited diseases it was shown that biotechnology based clinical work streams provide improved outcomes compared to traditional treatment strategies. With a classification accuracy of 94.6% (91.8% sensitivity, 93.4% specificity) our system reliably identifies the correct disease related risk groups and molecular sub-types while a drug matching rate of 93.2% in our treatment recommendation model shows we are highly capable of suggesting matching therapies, with 87.5% of patients showing a positive treatment response with individualized approaches. The significant decrease in adverse events (21.3% and improvement in efficacy (24.5%) demonstrates the benefits of a precision based treatment strategy, showing that science can indeed impact the health status of patients and that biotechnology can build bridges between the discovery phase in the laboratory and the clinical phase within healthcare providers/institutions. These findings will support the further implementation of biomarker driven medicine in the hospital environment and specific clinical practice guidelines. Additional future research work in this field should include more comprehensive implementation of Artificial Intelligence to enhance prediction within the clinical modeling component and enabling real-time precision medicine through constant patient observation and broader implementation of multi-omics platforms to increase the accuracy of the treatment prediction and efficiency across different disease types, leading to further improvements in personalized patient care, scalability, and sustainability.

References

- Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., ... & Vale, N. (2024). Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics*, 16(3), 332. <https://doi.org/10.3390/pharmaceutics16030332>
- Olorunsogo, T. O., Balogun, O. D., Ayo-Farai, O., Ogundairo, O., Maduka, C. P., Okongwu, C. C., & Onwumere, C. (2024). Bioinformatics and personalized medicine in the US: A comprehensive review: Scrutinizing the advancements in genomics and their potential to revolutionize healthcare delivery. *World Journal of Advanced Research and Reviews*, 21(1), 335-351. <https://doi.org/10.30574/wjarr.2024.21.1.0016>
- Manne, U., Srivastava, R. G., & Srivastava, S. (2005). Keynote review: Recent advances in biomarkers for cancer diagnosis and treatment. *Drug discovery today*, 10(14), 965-976. [https://doi.org/10.1016/S1359-6446\(05\)03487-2](https://doi.org/10.1016/S1359-6446(05)03487-2)
- Sunil Krishnan, G., Joshi, A., & Kaushik, V. (2021). Bioinformatics in personalized medicine. In *Advances in bioinformatics* (pp. 303-315). Singapore: Springer Singapore. https://doi.org/10.1007/978-981-33-6191-1_15

- Dey, A., Mitra, A., Pathak, S., Prasad, S., Zhang, A. S., Zhang, H., ... & Banerjee, A. (2023). Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer. *Technology in cancer research & treatment*, 22, 15330338231178403. <https://doi.org/10.1177/15330338231178403>
- Molla, G., & Bitew, M. (2024). Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. *Biomedicines*, 12(12), 2750. <https://doi.org/10.3390/biomedicines12122750>
- Yadav, S., Palei, N. N., Dinda, S. C., & Dhar, A. K. (2024). Drug delivery in biotechnology: present and future. *Concepts in pharmaceutical biotechnology and drug development*, 103-138. https://doi.org/10.1007/978-981-97-1148-2_7
- Pavez Lorié, E., Baatout, S., Choukér, A., Buchheim, J. I., Baselet, B., Dello Russo, C., ... & Yip, V. L. M. (2021). The future of personalized medicine in space: from observations to countermeasures. *Frontiers in bioengineering and biotechnology*, 9, 739747. <https://doi.org/10.3389/fbioe.2021.739747>
- Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., ... & Kloczkowski, A. (2022). Innovations in genomics and big data analytics for personalized medicine and health care: a review. *International journal of molecular Sciences*, 23(9), 4645. <https://doi.org/10.3390/ijms23094645>
- Taherdoost, H., & Ghofrani, A. (2024). AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. *Intelligent Pharmacy*, 2(5), 643-650. <https://doi.org/10.1016/j.ipha.2024.08.005>
- Akhood, N. (2021). Precision medicine: a new paradigm in therapeutics. *International journal of preventive medicine*, 12(1), 12. https://doi.org/10.4103/ijpvm.IJPVM_375_19
- Kiran, N. S., Yashaswini, C., Maheshwari, R., Bhattacharya, S., & Prajapati, B. G. (2024). Advances in precision medicine approaches for colorectal cancer: from molecular profiling to targeted therapies. *ACS pharmacology & translational science*, 7(4), 967-990. <https://doi.org/10.1021/acspsci.4c00008>
- Hampel, H., Gao, P., Cummings, J., Toschi, N., Thompson, P. M., Hu, Y., ... & Vergallo, A. (2023). The foundation and architecture of precision medicine in neurology and psychiatry. *Trends in Neurosciences*, 46(3), 176-198. <https://doi.org/10.1016/j.tins.2022.12.004>
- Hamdy, N. M., Basalious, E. B., El-Sisi, M. G., Nasr, M., Kabel, A. M., Nossier, E. S., & Abadi, A. H. (2024). Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine. *Current medical research and opinion*, 40(11), 1943-1961. <https://doi.org/10.1080/03007995.2024.2416985>
- Boniolo, F., Dorigatti, E., Ohnmacht, A. J., Saur, D., Schubert, B., & Menden, M. P. (2021). Artificial intelligence in early drug discovery enabling precision medicine. *Expert Opinion on Drug Discovery*, 16(9), 991-1007. <https://doi.org/10.1080/17460441.2021.1918096>
- Cajander, S., Kox, M., Scicluna, B. P., Weigand, M. A., Mora, R. A., Flohé, S. B., ... & Venet, F. (2024). Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. *The Lancet Respiratory Medicine*, 12(4), 305-322. [https://doi.org/10.1016/S2213-2600\(23\)00330-2](https://doi.org/10.1016/S2213-2600(23)00330-2)
- Corti, C., Cobanaj, M., Dee, E. C., Criscitiello, C., Tolaney, S. M., Celi, L. A., & Curigliano, G. (2023). Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. *Cancer treatment reviews*, 112, 102498. <https://doi.org/10.1016/j.ctrv.2022.102498>
- Tong, L., Shi, W., Isgut, M., Zhong, Y., Lais, P., Gloster, L., ... & Wang, M. D. (2023). Integrating multi-omics data with EHR for precision medicine using advanced artificial intelligence. *IEEE Reviews in Biomedical Engineering*, 17, 80-97. <https://doi.org/10.1109/RBME.2023.3324264>
- Su, J., Yang, L., Sun, Z., & Zhan, X. (2024). Personalized drug therapy: innovative concept guided with proteoformics. *Molecular & Cellular Proteomics*, 23(3). <https://doi.org/10.1016/j.mcpro.2024.100737>
- Brancato, V., Esposito, G., Coppola, L., Cavaliere, C., Mirabelli, P., Scapicchio, C., ... & Aiello, M. (2024). Standardizing digital biobanks: integrating imaging, genomic, and clinical data for precision medicine. *Journal of translational medicine*, 22(1), 136. <https://doi.org/10.1186/s12967-024-04891-8>